Antitumor effects of novel compound, guttiferone K, on colon cancer by p21Waf1/Cip1-mediated G0/G1 cell cycle arrest and apoptosis

International Journal of Cancer

Volumn 132, Issue 3, 2013, Pages 707-716

  Kan, Winnie Lai Ting ^a   Yin, Chun ^a   Xu, Hong Xi ^b   Xu, Gang ^c   To, Kenneth Kin Wah ^a   Cho, Chi Hin ^a   Rudd, John Anthony ^a   Lin, Ge ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c KUNMING INSTITUTE OF BOTANY   (China)

Author keywords

anti tumor; apoptosis; cell cycle; colon cancer; guttiferone K

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FLUOROURACIL; GUTTIFERONE K; KI 67 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER SIZE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN CONDENSATION; COLON CANCER; COLON MUCOSA; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIUM CELL; G0 PHASE CELL CYCLE CHECKPOINT; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANTHRACENES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOPHENONES; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN; COLONIC NEOPLASMS; CYCLIN D1; CYCLIN D3; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FLUOROURACIL; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KI-67 ANTIGEN; MALE; MICE; MICE, INBRED BALB C; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84870251010     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27694     Document Type: Article

References (43)

1. American Cancer Society, Inc. Leo and Gloria Rosen. 2011. Available at: http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/ colorectal-cancer-key-statistics. Last accessed 26 June 2011.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Chau I, Cunningham D,. Adjuvant therapy in colon cancer-what, when and how? Ann Oncol 2006; 17: 1347-59.
4. Wilkes GM,. Therapeutic options in the management of colon cancer: 2005 update. Clin J Oncol Nurs 2005; 9: 31-44.
5. Kosmider S,., Lipton L,. Adjuvant therapies for colorectal cancer. World J Gastroenterol 2007; 13: 3799-805.
6. Da Rocha BA, Lopes RM, Schwartsmann G,. Natural products in anticancer therapy. Curr Opin Pharmacol 2001; 1: 364-9.
7. Reutrakul V, Anantachoke N, Pohmakotr M, et al. Cytotoxic and anti-HIV caged xanthones from the resin and fruits of Garcinia hanburyi. Planta Med 2007; 73: 33-40.
8. Han QB, Xu HX,. Caged Garcinia xanthones: development since 1937. Curr Med Chem 2009; 16: 3775-96.
9. Han QB, Wang YL, Yang L, et al. Cytotoxic polyprenylated xanthones from the resin of Garcinia hanburyi. Chem Pharm Bull (Tokyo) 2006; 54: 265-7.
10. Rukachaisirikul V, Phainuphong P, Sukpondma Y, et al. Antibacterial caged-tetraprenylated xanthones from the stem bark of Garcinia scortechinii. Planta Med 2005; 71: 165-70.
11. Jang SW, Okada M, Sayeed I, et al. Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death. Proc Natl Acad Sci USA 2007; 104: 16329-34.
12. Sampath PD, Kannan V,. Mitigation of mitochondrial dysfunction and regulation of eNOS expression during experimental myocardial necrosis by alpha-mangostin, a xanthonic derivative from Garcinia mangostana. Drug Chem Toxicol 2009; 32: 344-52.
13. Kasibhatla S, Jessen KA, Maliartchouk S, et al. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci USA 2005; 102: 12095-100.
14. Pandey MK, Sung B, Ahn KS, et al. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood 2007; 110: 3517-25.
15. Yang Y, Yang L, You QD, et al. Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Lett 2007; 256: 259-66.
16. Yu J, Guo QL, You QD, et al. Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 2007; 28: 632-8.
17. Zhai D, Jin C, Shiau CW, et al. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 2008; 7: 1639-46.
18. Li Q, Cheng H, Zhu G, et al. Gambogenic acid inhibits proliferation of A549 cells through apoptosis-inducing and cell cycle arresting. Biol Pharm Bull 2010; 33: 415-20.
19. Qi Q, Lu N, Wang XT, et al. Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol 2008; 86: 386-95.
20. Yi T, Yi Z, Cho SG, et al. Gambogic acid inhibits angiogenesis and prostrate tumor growth by suppressing vascular endothelial growth factor receptor-2 signaling. Cancer Res 2008; 68: 1843-50.
21. Wu ZQ, Guo QL, You QD, et al. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull 2004; 27: 1769-74.
22. Guo Q, Qi Q, You Q, et al. Toxicological studies of gambogic acid and its potential targets in experimental animals. Basic Clin Pharmacol Toxicol 2006; 99: 178-84.
23. Qi Q, You Q, Gu H, et al. Studies on the toxicity of gambogic acid in rats. J Ethnopharmacol 2008; 117: 433-8.
24. Xu G, Kan WL, Zhou Y, et al. Cytotoxic acylphloroglucinol derivatives from the twigs of Garcinia cowa. J Nat Prod 2010; 73: 104-8.
25. Guo QL, You QD, Wu ZQ, et al. General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacol Sin 2004; 25: 769-74.
26. Chen J, Gu HY, Lu N, et al. Microtubule depolymerization and phosphorylation of c-Jun-N-terminal kinase-1 and p38 were involved in gambogic acid induced cell cycle arrest and apoptosis in human breast carcinoma cells. Life Sci 2008; 83: 103-9.
27. Belletti B, Nicoloso MS, Schiappacassi M, et al. p27(kip1) functional regulation in human cancer: a potential target for therapeutic designs. Curr Med Chem 2005; 12: 1589-605.
28. Chen CS, Lee CH, Hsieh CD, et al. Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins. Breast Cancer Res Treat 2011; 125: 73-87.
29. Bandoh N, Hayashi T, Takahara M, et al. Loss of p21 expression is associated with p53 mutations and increased cell proliferation and p27 expression is associated with apoptosis in maxillary sinus squamous cell carcinoma. Acta Otolaryngol 2005; 125: 779-85.
30. Brzezinski J, Migodzinski A, Toczek A, et al. Patterns of cyclin E, retinoblastoma protein, and p21Cip1/WAF1 immunostaining in the oncogenesis of papillary thyroid carcinoma. Clin Cancer Res 2005; 11: 1037-43.
31. Schondorf T, Gohring UJ, Becker M, et al. High apoptotic index correlates to p21 and p27 expression indicating a favorable oucome of primary breast cancer patients, but lacking prognostic significance in multivariate analysis. Pathobiology 2004; 71: 217-22.
32. Gartel AL, Tyner AL,. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002; 1: 639-49.
33. Li J, Zhang Y, Zhao J, et al. Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem 2011; 357: 31-8.
34. Pucci B, Kasten M, Giordano A,. Cell cycle and apoptosis. Neoplasia 2000; 2: 291-99.
35. Huerta S, Goulet EJ, Livingston EH,. Colon cancer and apoptosis. Am J Surg 2006; 191: 517-26.
36. Elmore S,. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35: 495-516.
37. Fulda S, Sieverts H, Friesen C, et al. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-29.
38. Prasad S, Ravindran J, Sung B, et al. Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther 2010; 9: 856-68.
39. Fan M, Chambers TC,. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat 2001; 5: 253-267.
40. Srivastava RK, Mi QS, Hardwick JM, et al. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 1999; 96: 3775-80.
41. Fan M, Goodwin ME, Birrer MJ, et al. The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. Cancer Res 2001; 61: 4450-8.
42. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-8.
43. Wagner EF, Nebreda AR,. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-49.